These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 26799352)

  • 1. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
    Cianfriglia M
    Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments for antibody-drug conjugate-based therapeutic approaches.
    de Goeij BE; Lambert JM
    Curr Opin Immunol; 2016 Jun; 40():14-23. PubMed ID: 26963132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
    Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
    Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.
    Beck A; Lambert J; Sun M; Lin K
    MAbs; 2012; 4(6):637-47. PubMed ID: 22909934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
    Sapra P; Betts A; Boni J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.
    Drachman JG; Senter PD
    Hematology Am Soc Hematol Educ Program; 2013; 2013():306-10. PubMed ID: 24319196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies and challenges for the next generation of antibody-drug conjugates.
    Beck A; Goetsch L; Dumontet C; Corvaïa N
    Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates for Cancer Treatment.
    Lambert JM; Berkenblit A
    Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
    Beck A; Senter P; Chari R
    MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules].
    Vigne E; Sassoon I
    Med Sci (Paris); 2014 Oct; 30(10):855-63. PubMed ID: 25311020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.